OncBioMune Pharmaceuticals

    OverviewSuggest Edit

    OncBioMune specializes in innovative cancer research. The Company owns the proprietary rights to a therapeutic cancer vaccine and patent-pending targeted therapies. The Company’s vaccines have been proven to be effective in cancer patients with virtually no toxicity, clearing a major hurdle in immunotherapy and oncology and positioning OncBioMune to deliver a new standard of cancer care. Using tumor antigens to immunize patients, OncBioMune’s vaccines can be used as a stand-alone therapeutic or as an adjunct to today’s or future cancer treatments to boost the immune system to attack cancer cells in relapsed, refractory or simply at-risk patients. The Company's approaches slow tumor cell proliferation, help avoid relapse, overcomes drug resistance and extends progression-free and overall survival. 
    TypePublic
    FoundedMarch 2005
    HQBaton Rouge, US
    Websiteoncbiomune.com

    Latest Updates

    Employees (est.) (Sep 2017)1
    Revenue (FY, 2014)$24

    OncBioMune Pharmaceuticals Office Locations

    OncBioMune Pharmaceuticals has an office in Baton Rouge
    Baton Rouge, US (HQ)
    11441 Industriplex Blvd #190
    Show all (1)

    OncBioMune Pharmaceuticals Financials and Metrics

    OncBioMune Pharmaceuticals Revenue

    OncBioMune Pharmaceuticals's revenue was reported to be $24 in FY, 2014
    USD

    Net income (Q1, 2019)

    (4.4m)

    EBIT (Q1, 2019)

    (563.1k)
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

    Revenue

    24.0

    General and administrative expense

    198.1k182.2k214.2k225.2k174.3k

    R&D expense

    85.3k94.4k103.9k204.6k

    Operating expense total

    534.2k807.6k1.8m2.5m1.8m
    Quarterly
    USDQ3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

    Revenue

    66.08.014.4k145.7k118.6k

    Cost of goods sold

    10.6k92.3k53.2k

    Gross profit

    3.8k53.4k65.4k

    Gross profit Margin, %

    26%37%55%
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

    Cash

    13.0k672.8k1.4k201.0

    Current Assets

    17.9k709.5k41.3k14.1k215.9k

    PP&E

    10.7k9.6k6.6k4.3k

    Total Assets

    349.2k726.6k57.3k27.2k226.6k
    Quarterly
    USDQ3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

    Cash

    62.5k8.9k38.6k10.4k4.6k184.6k366.5k12.8k10.6k142.5k111.9k83.6k2.1k2.2k50.3k

    Accounts Receivable

    170.0k93.4k

    Inventories

    52.6k104.6k106.2k

    Current Assets

    67.1k8.9k43.0k10.4k4.6k198.2k413.1k92.1k57.9k460.1k386.2k382.8k242.8k19.7k276.6k203.9k
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

    Net Income

    (757.4k)(990.4k)(2.0m)(20.5m)6.5m

    Depreciation and Amortization

    274.01.1k3.7k2.3k

    Accounts Payable

    1.3k(23.1k)111.3k164.6k172.1k

    Cash From Operating Activities

    (372.2k)(851.8k)(1.5m)(2.3m)(1.7m)
    Quarterly
    USDQ3, 2014Q1, 2015Q2, 2015Q1, 2016Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

    Net Income

    (376.4k)(93.1k)(92.1k)(195.0k)(341.8k)(444.3k)(1.0m)(1.4m)(2.8m)(3.0m)(9.1m)9.3m4.6m4.0m(4.4m)

    Depreciation and Amortization

    275.0549.0823.01.9k2.5k2.4k585.01.2k1.8k584.0

    Inventories

    4.7k(41.9k)(44.9k)

    Accounts Payable

    22.8k10.2k1.7k(56.8k)133.9k127.0k(420.0)148.7k89.1k(9.0k)2.8k79.3k162.7k
    Show all financial metrics

    OncBioMune Pharmaceuticals Online and Social Media Presence

    Embed Graph

    OncBioMune Pharmaceuticals Blogs

    OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers

    OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapy, is pleased to announce that it has entered into a consulting agr…

    OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer

    BATON ROUGE, La., Jan. 09, 2019 (GLOBE NEWSWIRE) — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today annou…

    Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer

    BATON ROUGE, La., Dec. 07, 2018 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to provide an upd…

    2018 Global Summit on Genitourinary Malignancies Presentation

    2018 Global Summit on Genitourinary Malignancies

    OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Development and Corporate Milestones

    BATON ROUGE, La., Oct. 31, 2018 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today provides an update on …

    OncBioMune CEO Dr. Jonathan Head Speaking at 2018 Global Summit on Genitourinary Malignancies

    BATON ROUGE, La., Oct. 31, 2018 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to inform shareho…
    Show more

    OncBioMune Pharmaceuticals Frequently Asked Questions

    • When was OncBioMune Pharmaceuticals founded?

      OncBioMune Pharmaceuticals was founded in March 2005.

    • How many employees does OncBioMune Pharmaceuticals have?

      OncBioMune Pharmaceuticals has 1 employees.

    • Who are OncBioMune Pharmaceuticals competitors?

      Competitors of OncBioMune Pharmaceuticals include Clovis Oncology, Nektar Therapeutics and AVEO Pharmaceuticals.

    • Where is OncBioMune Pharmaceuticals headquarters?

      OncBioMune Pharmaceuticals headquarters is located at 11441 Industriplex Blvd #190, Baton Rouge.

    • Where are OncBioMune Pharmaceuticals offices?

      OncBioMune Pharmaceuticals has an office in Baton Rouge.

    • How many offices does OncBioMune Pharmaceuticals have?

      OncBioMune Pharmaceuticals has 1 office.